MX2014015900A - Formulaciones de progesterona. - Google Patents

Formulaciones de progesterona.

Info

Publication number
MX2014015900A
MX2014015900A MX2014015900A MX2014015900A MX2014015900A MX 2014015900 A MX2014015900 A MX 2014015900A MX 2014015900 A MX2014015900 A MX 2014015900A MX 2014015900 A MX2014015900 A MX 2014015900A MX 2014015900 A MX2014015900 A MX 2014015900A
Authority
MX
Mexico
Prior art keywords
fatty acid
ultra
polyethylene glycol
micronized progesterone
esters
Prior art date
Application number
MX2014015900A
Other languages
English (en)
Inventor
Janice Louise Cacace
Peter H R Persicaner
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261661302P priority Critical
Priority to US201261662265P priority
Priority to US13/684,002 priority patent/US8633178B2/en
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Priority to PCT/US2013/023309 priority patent/WO2013112947A1/en
Priority to US13/843,362 priority patent/US20130338122A1/en
Priority to PCT/US2013/046442 priority patent/WO2013192248A1/en
Publication of MX2014015900A publication Critical patent/MX2014015900A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin

Abstract

Se describen formulaciones farmacéuticas de uso oral en la terapia de reemplazo hormonal que comprenden progesterona ultramicronizada, en donde la progesterona ultramicronizada se combina con un excipiente adecuado. Los excipientes preferidos comprenden ésteres de ácidos grasos de cadena media-glicoles y un surfactante no iónico que comprende un éster de ácidos grasos de polietilenglicol. En algunas modalidades, los ésteres de ácidos grasos de C8 a C18 de glicerol y polietilenglicol son los surfactantes no iónicos preferidos.
MX2014015900A 2011-11-23 2013-01-25 Formulaciones de progesterona. MX2014015900A (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US201261661302P true 2012-06-18 2012-06-18
US201261662265P true 2012-06-20 2012-06-20
US13/684,002 US8633178B2 (en) 2011-11-23 2012-11-21 Natural combination hormone replacement formulations and therapies
PCT/US2013/023309 WO2013112947A1 (en) 2012-01-26 2013-01-25 Transdermal hormone replacement therapies
US13/843,362 US20130338122A1 (en) 2012-06-18 2013-03-15 Transdermal hormone replacement therapies
PCT/US2013/046442 WO2013192248A1 (en) 2012-06-18 2013-06-18 Progesterone formulations

Publications (1)

Publication Number Publication Date
MX2014015900A true MX2014015900A (es) 2015-07-17

Family

ID=49756455

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014015900A MX2014015900A (es) 2011-11-23 2013-01-25 Formulaciones de progesterona.
MX2014015897A MX2014015897A (es) 2011-11-23 2013-06-18 Terapias de reemplazo hormonal transdermicas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014015897A MX2014015897A (es) 2011-11-23 2013-06-18 Terapias de reemplazo hormonal transdermicas.

Country Status (9)

Country Link
US (3) US20130338122A1 (es)
EP (3) EP2861234B1 (es)
JP (2) JP6298460B2 (es)
AU (3) AU2013277235B2 (es)
BR (2) BR112014031837A2 (es)
CA (2) CA2876964A1 (es)
MX (2) MX2014015900A (es)
WO (2) WO2013192250A1 (es)
ZA (1) ZA201500212B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018031576A1 (en) * 2016-08-08 2018-02-15 Baucom Karan Y Hormone delivery system and method
WO2015130807A1 (en) * 2014-02-25 2015-09-03 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US9795617B2 (en) 2009-06-18 2017-10-24 Baucom Institute for Longevity and Life Enhancement, Inc. Hormone delivery system and method
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2014006256A (es) 2011-11-23 2014-10-24 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
MX2014015900A (es) 2012-06-18 2015-07-17 Therapeuticsmd Inc Formulaciones de progesterona.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20150045335A1 (en) 2013-01-25 2015-02-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
US9180091B2 (en) * 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US20170216310A1 (en) 2014-10-22 2017-08-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017509630A (ja) * 2014-03-28 2017-04-06 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. プロゲステロン製剤
EP2944324A1 (de) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (1113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1967351A (en) 1930-10-06 1934-07-24 President And Board Hormone and process of obtaining the same
US2232438A (en) 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
GB452238A (en) 1934-08-24 1936-08-19 Chem Ind Basel Process for purifying progesterone preparations
US2379832A (en) 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
US2649399A (en) 1951-02-01 1953-08-18 Ayerst Mckenna & Harrison Conjugated oestrogenic quaternary ammonium salts and their preparation
GB720561A (en) 1952-04-17 1954-12-22 Frederick Victor Wells Improvements in preparations for application to the hair and scalp
GB848881A (en) 1955-12-27 1960-09-21 Upjohn Co Improvements in or relating to hormone compositions and the preparation thereof
GB874368A (en) 1957-12-09 1961-08-02 Irwin Irville Lubowe Improvements in anti-seborrheic and scalp preparations
FR1368727A (fr) 1961-05-04 1964-08-07 Roussel Uclaf Dérivés de l'estradiol et procédé de préparation
US3916898A (en) 1964-05-20 1975-11-04 Searle & Co Administration of medicaments and the like
US3755575A (en) 1965-01-26 1973-08-28 Squibb & Sons Inc Pharmaceutical compositions
FR5519M (es) 1966-06-07 1967-11-06
US3478070A (en) 1967-12-26 1969-11-11 American Home Prod Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof
GB1261348A (en) 1968-04-02 1972-01-26 Leo Ab Treatment of hair and scalp and compositions therefor
US3755573A (en) 1970-07-10 1973-08-28 Warner Lambert Co Fertility control empoying quinestrol and quingestanol acetate
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3923997A (en) 1971-05-11 1975-12-02 Rhodia Process for repelling dogs and cats from a selected area or from each other using {65 -n-alkyl-{65 -butyrolactones and {67 -n-alkyl-{67 -valerolactones
US3729566A (en) 1971-05-25 1973-04-24 Upjohn Co Rodent sterilant process
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US3948254A (en) 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3903880A (en) 1972-08-17 1975-09-09 Alza Corp Intrauterine device for managing the reproductive process
US4016251A (en) 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US3971367A (en) 1972-12-27 1976-07-27 Alza Corporation Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4014987A (en) 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
NL7506407A (nl) 1975-05-30 1976-12-02 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
US3977404A (en) 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4154820A (en) 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
FR2408345B1 (es) * 1976-11-30 1981-08-14 Besins Jean Louis
US4310510A (en) 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4393871A (en) 1977-06-27 1983-07-19 Vli Corporation Vaginal device
GB1589946A (en) 1977-12-14 1981-05-20 Kali Chemie Pharma Gmbh Enterally absorbable preparations and process for the production thereof
US4372951A (en) 1979-10-11 1983-02-08 Nichols Vorys Vaginal delivery for physiologic follicular-luteal steroid treatment
US4402695A (en) 1980-01-21 1983-09-06 Alza Corporation Device for delivering agent in vagina
US4215691A (en) 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
US4732763A (en) 1978-10-17 1988-03-22 Stolle Research And Development Corporation Active/passive immunization of the internal female reproductive organs
US4756907A (en) 1978-10-17 1988-07-12 Stolle Research & Development Corp. Active/passive immunization of the internal female reproductive organs
US4237885A (en) 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
US4384096A (en) 1979-08-27 1983-05-17 The Dow Chemical Company Liquid emulsion polymers useful as pH responsive thickeners for aqueous systems
AU538961B2 (en) 1980-06-09 1984-09-06 Alex Harvey Industries Limited Intra-vaginal device
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag Vaginalring
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4423151A (en) 1981-09-24 1983-12-27 Peter S. Brune Process for preparation of control for use in estrogen receptor tests
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4961931A (en) 1982-07-29 1990-10-09 Alza Corporation Method for the management of hyperplasia
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4610687A (en) 1984-08-06 1986-09-09 Board Of Trustees Operating Michigan State University Method for breeding control in female bovines
DE3510555A1 (de) 1985-03-21 1986-09-25 Schering Ag Estriolester
US4816257A (en) 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US4762717A (en) 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
JPH0419773B2 (es) * 1986-05-23 1992-03-31 Matsushita Electric Works Ltd
US6139868A (en) 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
CN1021196C (zh) 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4876249A (en) 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4865848A (en) 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US5538736A (en) 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US4900734A (en) 1987-08-27 1990-02-13 Maxson Wayne S Novel pharmaceutical composition containing estradiol and progesterone for oral administration
US5108995A (en) 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4942158A (en) 1988-10-13 1990-07-17 Eastman Kodak Transdermal steroid penetrant compositions and methods utilizing isopropanol and isobutanol
JP3238389B2 (ja) 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
US5064654A (en) 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US4973468A (en) 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
DE3916112C2 (es) 1989-05-16 1992-04-30 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
DE69010076T2 (de) 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
DE69007886D1 (de) 1989-07-21 1994-05-11 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US5130137A (en) 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
DE3933460C2 (es) 1989-10-06 1992-03-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5288496A (en) 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
DE4104385C1 (es) 1991-02-09 1992-08-13 Marika Dr.Med. 6509 Framersheim De Ehrlich
FR2673840B1 (es) 1991-03-14 1995-03-10 Lvmh Rech
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5811547A (en) 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US6342491B1 (en) 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
GB9113726D0 (en) 1991-06-25 1991-08-14 Inst Of Animal Physiology And Artificial animal foster mothers
US5653983A (en) 1991-07-19 1997-08-05 Lvmh Recherche Compositions for the pigmentation of the skin or of the hair containing an extract of Marrubium vulgare, the process for it's manufacture and it's
US5676968A (en) 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
FR2695561B1 (fr) 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
ES2211871T3 (es) 1992-09-28 2004-07-16 Adeza Biomedical Corporation Procedimiento para la deteccion de un parto prematuro.
AT239431T (de) 1992-10-21 2003-05-15 Gynetech Lab Inc Abgabesystem bestehend aus einem vaginaschwamm
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
FR2699406B1 (fr) 1992-12-21 1995-03-10 Commissariat Energie Atomique Films à base de copolymères, leurs applications dans des systèmes transdermiques et leurs procédés de préparation.
EP0676953B1 (en) 1992-12-29 1999-05-06 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
DE4301783C1 (de) 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
US5843979A (en) 1993-02-25 1998-12-01 Bristol-Myers Squibb Company Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5468736A (en) 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
SE9301171D0 (sv) 1993-04-07 1993-04-07 Ab Astra Pharmaceutical composition containing lipophilic drugs
US5762952A (en) 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
CA2160775C (en) 1993-05-06 2006-06-06 Reinhold Meconi Transdermal therapeutic system containing estradiol
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5595970A (en) 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
DE4329242A1 (de) 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
CA2165802A1 (en) 1993-09-29 1995-04-06 Eun Soo Lee Monoglyceride/lactate ester permeation enhancer for oxybutynin
DE4341444C2 (de) 1993-12-04 1996-03-14 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung
DE4344463A1 (de) 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
DE4400770C1 (de) 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
JP3021661B2 (ja) 1994-03-07 2000-03-15 セラテック・インコーポレーテッド 薬剤含有接着複合体の経皮放出デバイス
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2717688B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.
FR2717689B1 (fr) 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène.
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
WO1995028144A1 (en) 1994-04-13 1995-10-26 Ciba-Geigy Ag Temporally controlled drug delivery systems
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
WO1995030409A1 (en) 1994-05-05 1995-11-16 Merck Frosst Canada Inc. Topical polymeric drug delivery system
US5811416A (en) 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US5709844A (en) 1994-06-09 1998-01-20 The Regents Of The University Of California Transgenic mice expressing HPV early region oncogene develop progressive cervico-vaginal neoplasia
AT232743T (de) 1994-06-27 2003-03-15 Neutron Therapies Inc Bor enthaltende hormonanaloga und verfahren fuer ihre verwendung zur bildlichen darstellung oder zum abtoeten von zellen, die hormonrezeptoren besitzen
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
FR2722984B1 (fr) 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
DE4429374C1 (de) 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
US5735801A (en) 1994-08-25 1998-04-07 Caillouette; James C. Estrogen or estradiol need determination by vaginal acidity determination
US5916176A (en) 1994-08-25 1999-06-29 Caillouette; James C. Estrogen or estradiol need determination by vaginal or urethral acidity determination
US5762614A (en) 1994-08-25 1998-06-09 Caillouette; James C. Estrogen or estradiol need determination by vaginal acidity determination
US6402705B1 (en) 1994-08-25 2002-06-11 James C. Caillouette Body moisture test apparatus and method
DK0781122T3 (da) 1994-09-14 2000-10-30 Minnesota Mining & Mfg Matrix til transdermal lægmiddelafgivelse
US6613757B1 (en) 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
IL115445A (en) 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
FR2725623B1 (es) 1994-10-18 1997-02-21
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5571933A (en) 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
EP0787488A4 (en) 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co Percutaneously absorbable patch
US5686100A (en) 1994-11-22 1997-11-11 E.R. Squibb & Sons, Inc. Prophylactic and therapeutic treatment of skin sensitization and irritation
US5885974A (en) 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor
FR2728463B1 (es) 1994-12-21 1997-02-21
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
DE19500662C2 (de) 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
US5516528A (en) 1995-01-13 1996-05-14 Wake Forest University Dietary phytoestrogen in estrogen replacement therapy
US5547948A (en) 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
FR2729854B1 (es) 1995-01-26 1997-03-07
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5565199A (en) 1995-02-07 1996-10-15 Page; Elliot W. Systems and methods for the synthesis of natural base steroidal hormones and more especially estrogens and progesterone and estrogen-like and progesterone-like compounds and their derivatives derived as phytohormones from herbaceous plants
US5609617A (en) 1995-02-21 1997-03-11 C. Norman Shealy Method for enhancement of dehydroepiandrosterone
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5693335A (en) 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US5679573A (en) 1995-07-27 1997-10-21 Abbott Laboratories Stabilized aqueous steroid immunoassay standards with cyclodextrins
US6245347B1 (en) 1995-07-28 2001-06-12 Zars, Inc. Methods and apparatus for improved administration of pharmaceutically active compounds
US5567831A (en) 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US5840327A (en) 1995-08-21 1998-11-24 Alza Corporation Transdermal drug delivery device having enhanced adhesion
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
FR2739032B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US6551611B2 (en) 1995-09-28 2003-04-22 Schering Aktiengesellschaft Hormone replacement therapy method
US5922349A (en) 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
FR2739558B1 (fr) 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
DE19540253C2 (de) 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
GB9522403D0 (en) 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5770176A (en) 1995-12-08 1998-06-23 Chiron Diagnostics Corporation Assays for functional nuclear receptors
DE19548332A1 (de) 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
DE19549264A1 (de) 1995-12-23 1997-06-26 Schering Ag Verfahren und Kit zur Kontrazeption
US5789442A (en) 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
EP0785211A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New substituted 19-nor-pregnane derivatives
EP0785212A1 (en) 1996-01-22 1997-07-23 Laboratoire Theramex New 19-nor-pregnene derivatives
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
FR2747042B1 (fr) 1996-04-05 1998-06-05 Besins Iscovesco Lab Medicament a base de progesterone et d'oestradiol
NZ286492A (en) 1996-05-01 1998-02-26 Dec International Nz Ltd Subst Intra vaginal devices for synchronising oestrus of animals is made up of cured silicone rubber material with 5% by weight of progesterone
US6040340A (en) 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
CN1245982C (zh) 1996-05-09 2006-03-22 阿姆瑞德手术有限公司 哮喘和气道疾病的治疗
JP2000513336A (ja) 1996-05-22 2000-10-10 シュミルラー,デニス,エル. 薬物の経皮送達のための組成物、方法及びデバイス
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
DE19629468A1 (de) 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
DE69731302D1 (de) 1996-07-22 2004-11-25 Renovo Ltd Verwendung von substanzen, die die östrogen wirkung fördern, zur behandlung von wunden
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6227202B1 (en) 1996-09-03 2001-05-08 Maulana Azad Medical College Method of organogenesis and tissue regeneration/repair using surgical techniques
JP2002505736A (ja) 1996-09-06 2002-02-19 ネーデルランドセ・オルガニザテイエ・フール・テゲパスト―ナトウールベテンシヤツペリーク・オンデルツエク・テイエヌオー 抗受胎薬またはエストロゲンおよび/またはプロゲステロンの置換もしくは補充の副作用のスクリーニング法
US20040176336A1 (en) 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
FR2753626B1 (fr) 1996-09-20 1998-11-06 Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
CN1238678A (zh) 1996-10-18 1999-12-15 友联坎普公司 酯封端聚酰胺凝胶
CA2263334A1 (en) 1996-10-30 1998-05-07 Sonal R. Patel Fatty acid esters of lactic acid salts as permeation enhancers
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
US5942243A (en) 1996-11-12 1999-08-24 Polytherapeutics, Inc. Mucoadhesive compositions for administration of biologically active agents to animal tissue
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
US20060014728A1 (en) 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
DE19654609A1 (de) 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE19700913C2 (de) 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US20010023261A1 (en) 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
KR100215027B1 (ko) 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
US5827200A (en) 1997-01-27 1998-10-27 Caillouette; James C. Method and apparatus for detecting amine producing organisms in the vagina
DE19705229C2 (de) 1997-02-12 1999-04-15 Hesch Rolf Dieter Prof Dr Med Verwendung von drei Hormonkomponenten zur hormonalen Kontrazeption zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
IT1291362B1 (it) 1997-05-13 1999-01-07 Vectorpharma Int Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi
KR100583275B1 (ko) 1997-05-28 2006-05-24 인터랙 돼지용 질내 삽입기구
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
US6039968A (en) 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19728517C2 (de) 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Sexualsteroidhormonen und Verfahren zu seiner Herstellung
DE19728516C2 (de) 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US20040234606A1 (en) 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US8765177B2 (en) 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
GB9720470D0 (en) 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US20040044080A1 (en) 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
WO1999025333A1 (en) 1997-11-19 1999-05-27 Humanetics Corporation USE OF Δ5-ANDROSTENE-3β-OL-7,17-DIONE IN THE TREATMENT OF LUPUS ERYTHEMATOSUS
US6692763B1 (en) 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6503896B1 (en) 1997-12-24 2003-01-07 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
IT1298575B1 (it) 1998-02-06 2000-01-12 Vectorpharma Int Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di
US6312703B1 (en) 1998-02-06 2001-11-06 Lecigel, Llc Compressed lecithin preparations
US6001846A (en) 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6028057A (en) 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE19807791A1 (de) 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
FR2776191B1 (fr) 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
US20030040790A1 (en) 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
AU3567699A (en) 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
FR2777784B1 (fr) 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6277418B1 (en) 1998-06-02 2001-08-21 Baylor College Of Medicine Corn extract contraceptive
FR2779438B1 (fr) 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
DE19825591A1 (de) 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
NZ330726A (en) 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
AU4972599A (en) 1998-07-07 2000-01-24 Transdermal Technologies, Inc. Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof
US6294188B1 (en) 1998-07-09 2001-09-25 Aviana Biopharm Inc. Methods involving changing the constitutive and stimulated secretions of the local reproductive system of women
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
DE19834931A1 (de) 1998-07-28 2000-02-24 Jenapharm Gmbh Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie
DE19834007C1 (de) 1998-07-29 2000-02-24 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung
US20070015698A1 (en) 1998-07-30 2007-01-18 United States Of America As Represented By The Secretary Of Health Treatment of skin, and wound repair, with thymosin beta 4
US20030181353A1 (en) 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
AT315033T (de) 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6087352A (en) 1998-08-17 2000-07-11 Trout; William E. Use of Zeranol to modulate reproductive cycles
US20020169205A1 (en) 1998-09-29 2002-11-14 Krzysztof Chwalisz Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents
NZ511072A (en) 1998-10-05 2004-03-26 Penn State Res Found Method for enhancing receptor-mediated cellular internalization using a composition of an active agent and a viscous material and an enhancer
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
TR200101790T2 (tr) 1998-12-23 2001-10-22 Idea Ag. Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
GB9828480D0 (en) 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
WO2000045795A2 (en) 1999-02-05 2000-08-10 Cipla Limited Topical sprays comprising a film forming composition
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6080118A (en) 1999-02-25 2000-06-27 Blythe; Cleveland Vaginal probe and method of using same
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
DE19911799A1 (de) 1999-03-17 2000-09-28 Lohmann Therapie Syst Lts Sammelpackung zur Entnahme von befüllten Beuteln in vorgebener Reihenfolge
CA2267743C (en) 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6974569B2 (en) 1999-05-03 2005-12-13 The Procter & Gamble Company Shampoos providing a superior combination anti-dandruff efficacy and condition
US6649155B1 (en) 1999-05-03 2003-11-18 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing certain cationic polymers
US6451300B1 (en) 1999-05-03 2002-09-17 The Procter & Gamble Company Anti-dandruff and conditioning shampoos containing polyalkylene glycols and cationic polymers
US8663692B1 (en) 1999-05-07 2014-03-04 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
DE60006380T2 (de) 1999-05-13 2004-05-13 Hisamitsu Pharmaceutical Co., Inc., Tosu Pflaster
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
US6645947B1 (en) 1999-05-20 2003-11-11 Chitogenics, Inc. Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1183010A2 (en) 1999-06-04 2002-03-06 ALZA Corporation Implantable gel compositions and method of manufacture
US6465004B1 (en) 1999-06-05 2002-10-15 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
PE20010404A1 (es) 1999-06-11 2001-04-09 Watson Pharmaceuticals Inc Combinacion de esteroides androgenicos no orales y compuestos estrogenicos y su uso en mujeres
GB9914648D0 (en) 1999-06-24 1999-08-25 Univ Birmingham Control of infra-ocular pressure
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6303132B1 (en) 1999-07-16 2001-10-16 Ardell H. Nelson Administering progesterone using EMU oil
KR20010010393A (ko) 1999-07-20 2001-02-05 김윤 소수성 고분자와 친수성 고분자의 생분해성 블록 공중합체 및이를 포함하는 약물 전달체 조성물
NZ337318A (en) 1999-08-18 2002-07-26 Interag Dispensing apparatus for dispensing same or different materials for at least two reservoirs
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013836A1 (en) 1999-08-26 2001-03-01 West Virginia University Cervical agent delivery system
CA2384679A1 (en) 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US6479545B1 (en) 1999-09-30 2002-11-12 Drugtech Corporation Formulation for menopausal women
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6436633B1 (en) 1999-10-22 2002-08-20 The Pennsylvania State University Human xenografts for microbicide testing and anatomical modeling
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AUPQ419099A0 (en) 1999-11-23 1999-12-16 Ko, Thomas Sai Ying Novel compositions and methods
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7384650B2 (en) 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US20020012710A1 (en) 1999-11-29 2002-01-31 Rimonest Ltd. Pomegranate products useful in improving health and methods of use thereof
US20040191276A1 (en) 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6708822B1 (en) 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US20010032125A1 (en) 1999-12-20 2001-10-18 Sundeep Bhan Activation of coupons based on quiz or questionnaire
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
BR0108107A (pt) 2000-01-28 2003-03-11 Endorech Inc Moduladores seletivos dos receptores de estrogênio em combinação com estrogênios; kits e composições farmacêuticas para praticar tal combinação; bem como a administração da referida combinação
FR2804603B1 (fr) 2000-02-04 2004-01-23 Rhodia Chimie Sa Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
WO2001060325A1 (en) 2000-02-16 2001-08-23 Bentley Pharmaceuticals, Inc. Pharmaceutical composition
CA2406871A1 (en) 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
US7989436B2 (en) 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US7459445B2 (en) 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US20010034340A1 (en) 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
IL135335A (en) 2000-03-29 2013-12-31 Lycored Natural Prod Ind Ltd Use of carotenoids in the preparation of medicaments for preventing hormone induced adverse effects and pharmaceutical compositions comprising carotenoids
DE60121928T2 (de) 2000-03-31 2007-03-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Verfahren zur herstellung von den trans-4-n-butylcyclohexanoicsaüre- und undecanoicsaüreestern von (7-alpha,11-beta)-dimethyl-17 beta -hydroxy-4-estren-3-one und deren medizynische anwendung
CZ20023382A3 (cs) 2000-04-12 2003-02-12 Schering Aktiengesellschaft Substituované estratrieny jako selektivně účinné estrogeny
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US8119138B2 (en) 2000-05-10 2012-02-21 Signe Biopharma Inc. Anti-estrogen and immune modulator combinations for treating breast cancer
US6495534B2 (en) 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
KR100452972B1 (ko) 2000-05-16 2004-10-14 주식회사 삼양사 경피투여용 하이드로젤 조성물
GB0015617D0 (en) 2000-06-26 2000-08-16 Vectura Ltd Improved preparations for dermal delivery of active substances
US20030114420A1 (en) 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US6740333B2 (en) 2000-07-07 2004-05-25 Anestic Aps Suppository and composition comprising at least one polyethylene glycol
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
AU7709901A (en) 2000-07-24 2002-02-05 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
US20020119174A1 (en) 2000-07-26 2002-08-29 Gardlik John Michael Compositions useful for regulating hair growth containing metal complexes of oxidized carbohydrates
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
EP1323430B1 (en) 2000-08-03 2007-03-14 Antares Pharma IPL AG Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
GB0021317D0 (en) 2000-08-30 2000-10-18 Queen Mary & Westfield College Transdermal pharmaceutical delivery composition
DE10045380A1 (de) 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
PT1319007E (pt) 2000-09-19 2006-05-31 Squibb Bristol Myers Co Compostos de succinimida heterociclicos fundidos e seus analogos enquanto moduladores da funcao dos receptores hormonais nucleares
PL365047A1 (xx) 2000-09-20 2004-12-27 Nycomed Pharma As Wytwarzanie emulsji i ich koncentratów
US20020119187A1 (en) 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
EP1334724A4 (en) 2000-10-16 2007-05-02 Hisamitsu Pharmaceutical Co Compositions for external preparations
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
BR0115067A (pt) 2000-10-30 2004-04-06 Univ Zuerich Análogos de gnrh para tratamento de incontinência urinária
US6328987B1 (en) 2000-11-03 2001-12-11 Jan Marini Skin Research, Inc. Cosmetic skin care compositions containing alpha interferon
US20030113268A1 (en) 2000-11-10 2003-06-19 Mina Buenafae Degradation-resistant glucocorticosteroid formulations
US6605605B2 (en) 2000-11-13 2003-08-12 Milton Hammerly Estrogenic substances combined with cruciferous indole compounds
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
FR2816838B1 (fr) 2000-11-17 2004-12-03 Oreal Utilisation de derives de l'acide 2-oxothiazolidine- 4-carboxylique comme agents prodesquamants
KR20030051843A (ko) 2000-11-17 2003-06-25 워너-램버트 캄파니 엘엘씨 성기능 장애의 치료
US20040022820A1 (en) 2001-11-28 2004-02-05 David Anderson Reversed liquid crystalline phases with non-paraffin hydrophobes
AUPR184500A0 (en) 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
AU2002245104B2 (en) 2000-12-11 2006-08-17 Testocreme, Llc Topical testosterone formulations and associated methods
EE05358B1 (et) 2000-12-14 2010-12-15 Ortho-Mcneil Pharmaceutical, Inc. Steroidhormoonprodukt ja selle valmistamismeetod
US7018992B2 (en) 2000-12-15 2006-03-28 Novo Nordisk A/S Hormone composition
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20020151530A1 (en) 2000-12-22 2002-10-17 Leonard Thomas W. Method of treating hormonal deficiencies in women undergoing estrogen replacement therapy
US20020107230A1 (en) 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
WO2002053138A2 (en) 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020197286A1 (en) 2001-01-16 2002-12-26 Jane Brandman Method for preventing and treating skin aging
FR2820320B1 (fr) 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7381427B2 (en) 2001-02-09 2008-06-03 Mickey Miller Seborrheic keratosis treatment
NZ509894A (en) 2001-02-09 2002-11-26 Interag A "T" or "Y" shaped intravaginal device suitable for delivery of pharmaceuticals such as progesterone
US7303763B2 (en) 2001-02-12 2007-12-04 Watson Laboratories, Inc. Compositions for conjugated estrogens and associated methods
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002326291A1 (en) 2001-02-28 2003-01-02 Hiroshi Deguchi Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
US20020169150A1 (en) 2001-03-16 2002-11-14 Wyeth Hormone replacement therapy
WO2002078604A2 (en) 2001-03-30 2002-10-10 Elan Transdermal Technologies, Inc. Transdermal delivery of bioactive material
US20020142941A1 (en) 2001-03-30 2002-10-03 Pro Duct Health, Inc. Intraductal treatment targeting methylated promoters in breast cancer
EP1385459A2 (en) 2001-03-30 2004-02-04 Elan Pharmaceuticals, Inc. Transdermal delivery of pergolide
US20040131670A1 (en) 2001-04-17 2004-07-08 Ping Gao Pellicle-resistant gelatin capsule
US6860859B2 (en) 2001-04-20 2005-03-01 Monsanto Technology Llc Apparatus and method for detection of estrus and/or non-pregnancy
US20070021360A1 (en) 2001-04-24 2007-01-25 Nyce Jonathan W Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
US20120322779A9 (en) 2001-04-25 2012-12-20 Rhonda Voskuhl Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20050209208A1 (en) 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
EP1390038A2 (en) 2001-05-16 2004-02-25 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
AT350041T (de) 2001-05-18 2007-01-15 Pantarhei Bioscience Bv Pharmaceutishe zusammensetzung für die hormonersatztherapie
JP4865958B2 (ja) 2001-05-23 2012-02-01 エスエス製薬株式会社 鎮痛抗炎症局所作用型の貼付剤
US20020193356A1 (en) 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US20020193758A1 (en) 2001-06-18 2002-12-19 Sca Hygiene Products Ab Product
KR100988542B1 (ko) 2001-06-18 2010-10-20 노벤 파머수티컬즈, 인코퍼레이티드 경피 시스템에서의 강화된 약물 전달
US7094228B2 (en) 2001-07-31 2006-08-22 Zars, Inc. Methods and formulations for photodynamic therapy
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
DE10141652B4 (de) 2001-08-24 2011-04-07 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System auf der Basis von Polyacrylat-Haftklebern ohne funktionelle Gruppen und seine Verwendung
EP1455888B1 (en) 2001-08-29 2009-04-29 PharmaKodex Limited Topical administration device
US6911438B2 (en) 2001-09-12 2005-06-28 Jonathan V. Wright Hormone replacement formulation
DE10146541A1 (de) 2001-09-21 2003-04-17 Kade Pharma Fab Gmbh Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung
AU2002330102A1 (en) 2001-09-28 2003-04-14 Aspenbio, Inc. Bovine pregnancy test
JP2005507394A (ja) 2001-09-29 2005-03-17 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツングSolvay Pharmaceuticals GmbH エストロゲン/ゲスターゲン組合せ療法およびその使用
US20030175329A1 (en) 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AR026386A1 (es) 2001-10-24 2003-02-12 Massara Julio Eduardo Un dispositivo intravaginal que contiene progesterona, util como inductor de celo en bovinos productores de carne y leche, y el procedimiento paraprepararlo
US7815936B2 (en) 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
US20070196415A1 (en) 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
EP1443966B1 (en) 2001-11-15 2007-03-14 Pantarhei Bioscience B.V. Method of preventing or treating benign gynaecological disorders
PT1446128E (pt) 2001-11-15 2007-03-30 Pantarhei Bioscience Bv Utilização de compostos estrogénicos combinados com compostos progestagénicos na terapia hormonal de substituição
EP1458361A4 (en) 2001-11-20 2007-04-25 Advanced Inhalation Res Inc Compositions for sustained action product delivery
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
DE10159120B4 (de) * 2001-12-01 2006-08-17 Lts Lohmann Therapie-Systeme Ag Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung
AU2002353118A1 (en) 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
ES2188426B1 (es) 2001-12-12 2004-11-16 Rosalia Pidal Fernandez Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
TWI332400B (en) 2001-12-14 2010-11-01 Solvay Pharm Gmbh Preformulation for the tableting of natural mixtures of conjugated estrogens
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
US7329654B2 (en) 2001-12-19 2008-02-12 Janssen Pharmaceutica N.V. Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2003055468A1 (en) 2001-12-21 2003-07-10 Shire Laboratories Inc. Oral capsule formulation with increased physical stability
US6962908B2 (en) 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US8591951B2 (en) 2002-05-15 2013-11-26 Joachim B. Kohn Tri-block copolymers for nanosphere-based drug delivery
US6878518B2 (en) 2002-01-22 2005-04-12 The Trustees Of The University Of Pennsylvania Methods for determining steroid responsiveness
US6901278B1 (en) 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
US20060052341A1 (en) 2002-02-08 2006-03-09 Brian Cornish Control of a biological function
NZ517094A (en) 2002-02-08 2005-03-24 Advanced Animal Technology Ltd Improvements in and relating to substance delivery device
GB0203276D0 (en) 2002-02-12 2002-03-27 Novartis Ag Organic compounds
EP1572908A4 (en) 2002-02-14 2008-10-22 William J Rutter Chimeric molecules for cleavage in a treated host
DE10206390A1 (de) 2002-02-15 2003-08-28 Bionorica Ag Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten
RS50909B (en) 2002-02-21 2010-08-31 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
US7727720B2 (en) 2002-05-08 2010-06-01 Ravgen, Inc. Methods for detection of genetic disorders
US20030175333A1 (en) 2002-03-06 2003-09-18 Adi Shefer Invisible patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients onto the skin
US7741116B2 (en) 2002-03-06 2010-06-22 University Of Cincinnati Surgical device for skin therapy or testing
CA2478165A1 (en) 2002-03-11 2003-09-25 Janssen Pharmaceutica N.V. Sulfatase inhibiting progestogen-only contraceptive regimens
PT1482925E (pt) 2002-03-11 2007-04-30 Bayer Schering Pharma Ag 5-(2-hidroxi-3-'1-(3-trifluorometilfenil)-ciclopropil]-propionilamino-ftalida e compostos relacionados com actividade de modulação do receptor da progesterona para utilização no controlo de fertilidade e terapia de substituição hormonal
CN1652797A (zh) 2002-03-11 2005-08-10 詹森药业有限公司 连续使用抑制硫酸酯酶的孕激素的避孕给药方案
US20030229057A1 (en) 2002-03-11 2003-12-11 Caubel Patrick Michel Continuous sulfatase inhibiting progestogen hormone replacement therapy
CN1622810A (zh) 2002-03-14 2005-06-01 华生制药公司 孕酮口服药物传输系统
DE10211832A1 (de) 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion
FR2837100B1 (fr) 2002-03-18 2004-07-23 Flamel Tech Sa Comprimes a bases de microcapsules a liberation modifiee
EP1487416B1 (en) 2002-03-26 2009-12-02 Teva Pharmaceutical Industries Ltd. Drug microparticles
US7300926B2 (en) 2002-04-01 2007-11-27 University Of Florida Research Foundation, Inc. Steroidal quinols and their use for estrogen replacement therapy
US20030191096A1 (en) 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
US20040235812A1 (en) 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
IL164163D0 (en) 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
WO2003090671A2 (en) 2002-04-23 2003-11-06 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
DE10218109A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
NZ548754A (en) 2002-04-26 2008-06-30 Schering Aktiengellschaft Treatment of hypertension in women receiving hormone replacement therapy
CA2484173A1 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
AU2003231082A1 (en) 2002-05-02 2003-11-17 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US6821524B2 (en) 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
US6943021B2 (en) 2002-06-07 2005-09-13 Mattek Corporation Three dimensional vaginal tissue model containing immune cells
EP1511498B1 (en) 2002-06-11 2012-11-21 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
US20040048900A1 (en) 2002-06-17 2004-03-11 Pamela Flood Nicotine and/or nicotine agonists for the treatment of general anesthetic effects and side effects
FR2841138B1 (fr) 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20050186141A1 (en) 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
WO2004011008A1 (de) 2002-07-25 2004-02-05 Schering Aktiengesellschaft ZUSAMMENSETZUNG, ENTHALTEND EIN ANDROGENES 11β-HALOGENSTEROID UND EIN GESTAGEN SOWIE MÄNNLICHES KONTRAZEPTIVUM AUF BASIS DIESER ZUSAMMENSETZUNG
US6960337B2 (en) 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
TR200201966A2 (tr) 2002-08-07 2004-02-23 Edko Pazarlama Tanitim Ticaret Limited Şirketi Farmasötik terkip.
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
AT452645T (de) 2002-08-20 2010-01-15 Univ Singapore Phytoprogestogenen extrakten aus rhizoma ligusticum chuanxiong und ihre verwendungszwecke
KR20050059092A (ko) 2002-08-28 2005-06-17 로버트 캐스퍼 에스트로겐 보충 요법
AU2003278766A1 (en) 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
EP1551415B1 (en) 2002-09-05 2009-12-23 Pantarhei Bioscience B.V. Oral pharmaceutical composition comprising 15-hydroxytestosterone and its analogues
US6967194B1 (en) 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US7458982B2 (en) 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10247399A1 (de) 2002-10-08 2004-04-29 Schering Ag Pharmazeutische Zubereitungen, Verwendung dieser Zubereitung und Verfahren zur Erhöhung der Bioverfügbarkeit von peroral zu applizierenden Arzneistoffen
US20040146894A1 (en) 2002-10-14 2004-07-29 Warrington Janet A. Methods of diagnosing and treating stress urinary incontinence
GB0224415D0 (en) 2002-10-21 2002-11-27 Medical Res Council Compositions
PT1556058E (pt) 2002-10-23 2008-03-20 Pantarhei Bioscience Bv Composições farmacêuticas que compreendem derivados do estretol para serem utilizadas no tratamento do cancro
US20060193789A1 (en) 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
CA2502986C (en) 2002-10-25 2011-08-23 Foamix Ltd. Cosmetic and pharmaceutical foam
DE10249853A1 (de) 2002-10-25 2004-05-13 Liedtke, Rainer K., Dr. Pflasterartige Chip-Systeme zur thermodynamischen Kontrolle topisch dermaler und transdermaler Systeme
WO2004037843A2 (en) 2002-10-25 2004-05-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
IL152486D0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060018937A1 (en) 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20040087564A1 (en) 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US20040138103A1 (en) 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
US20040093261A1 (en) 2002-11-08 2004-05-13 Vivek Jain Automatic validation of survey results
US20040089308A1 (en) 2002-11-13 2004-05-13 Welch Robert A. Cervical ring to deliver medication
US20040097468A1 (en) 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7674783B2 (en) 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
CA2508536A1 (en) 2002-12-04 2004-06-17 Technologies Biolactis Inc. An exopolysaccharides delivery system for active molecules
FR2848112B1 (fr) 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
US20040115226A1 (en) 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
US20040115287A1 (en) 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
FR2849380A1 (fr) 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US20060034904A1 (en) 2002-12-31 2006-02-16 Ultra-Sonic Technologies, L.L.C. Transdermal delivery using emcapsulated agent activated by ultrasound and or heat
FR2849597B1 (fr) 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
US7572780B2 (en) 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
US20090318558A1 (en) 2003-02-12 2009-12-24 Jae-Hwan Kim Solvent system of hardly soluble drug with improved dissolution rate
US20040161435A1 (en) 2003-02-14 2004-08-19 Gupta Shyam K. Skin Firming Anti-Aging Cosmetic Mask Compositions
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20060194775A1 (en) 2003-02-20 2006-08-31 University Of Pittsburgh Estradiol metabolites for the treatment of pulmonary hypertension
MXPA05008778A (es) 2003-02-21 2006-05-25 Schering Ag Emplaste transdermico estable a uv.
FR2851918B1 (fr) 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US6956099B2 (en) 2003-03-20 2005-10-18 Arizona Chemical Company Polyamide-polyether block copolymer
CN100569747C (zh) 2003-03-31 2009-12-16 科学与工业研究会 巯基-苯基-萘基-甲烷衍生物及其制备
US20040191207A1 (en) 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
RU2339364C2 (ru) 2003-04-29 2008-11-27 Н.В.Органон, Nl Способ затвердевания с применением антирастворителя
JP4898431B2 (ja) 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
WO2004097002A2 (en) 2003-04-29 2004-11-11 The Miriam Hospital SELECTIVE TESTICULAR 11β-HSD INHIBITORS AND METHODS OF USE THEREOF
US20040219124A1 (en) 2003-05-01 2004-11-04 Gupta Shyam K. Cosmetic and Pharmaceutical Masks Based on Ion-Pair Delivery System
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び/又はプロゲストゲン含有外用貼付剤
US7925519B2 (en) 2003-05-20 2011-04-12 Medencentive, Llc Method and system for delivery of healthcare services
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
AT340580T (de) 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
US20040243437A1 (en) 2003-05-30 2004-12-02 Grace Joseph P. Compensated electronic consults
US7668735B2 (en) 2003-05-30 2010-02-23 Mdrxdirect Inc. Compensated electronic consults
US20090227025A1 (en) 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
US20040253319A1 (en) 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
EA026709B1 (ru) 2003-06-13 2017-05-31 Джон Клод Савуар Способ получения композиции эстрадиола с медленным высвобождением (варианты)
US20040259852A1 (en) 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US20110318405A1 (en) 2003-06-25 2011-12-29 Charles Erwin Chemical Combination and Method for Increasing Delivery of Coenzyme Q10
AU2004251783B2 (en) 2003-06-27 2009-12-10 Bayer Essure, Inc. Methods and devices for occluding body lumens and/or for delivering therapeutic agents
US7074779B2 (en) 2003-07-02 2006-07-11 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors
ES2316995T3 (es) 2003-07-08 2009-04-16 Novartis Ag Uso de rapamicina y derivados de rapamicida para el tratamiento de la perdida osea.
CA2532212A1 (en) 2003-07-11 2005-01-27 Macrochem Corporation Pharmaceutical compositions for topical application
WO2005009342A2 (en) 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
JP2007504131A (ja) 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
PL1660009T3 (pl) 2003-09-03 2015-08-31 Miscon Trading S A Sposoby leczenia endometriozy
EP1663185B1 (en) 2003-09-22 2008-12-10 onepharm Research & Development GmbH Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
JP2005104862A (ja) 2003-09-29 2005-04-21 Meiji Milk Prod Co Ltd 加齢黄斑変性治療剤
DK1670440T3 (da) 2003-09-29 2014-07-07 Novo Nordisk As HRT formuleringer
EP2409690A3 (en) 2003-09-29 2012-07-18 Novo Nordisk Femcare AG Improved stability of progestogen formulations
US7247625B2 (en) 2003-10-09 2007-07-24 Wyeth 6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
HU0303313A2 (hu) 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005039490A2 (en) 2003-10-16 2005-05-06 The Administrators Of The Tulane Educational Fund Methods and compositions for treating cancer
EP1680089B1 (en) 2003-10-22 2013-09-11 Lidds AB Composition comprising biodegradable hydrating ceramics for controlled drug delivery
WO2005039505A2 (en) 2003-10-24 2005-05-06 Nora, Llc Compositions and methods for healthy pregnancy
US20050101579A1 (en) 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
AT319426T (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
AT410171T (de) 2003-11-14 2008-10-15 Warner Chilcott Co Inc Graduierte östrogen-kontrazeptiva
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1535618A1 (en) 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
US20050186183A1 (en) 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
CA2548281C (en) 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
JP2007520262A (ja) 2003-12-10 2007-07-26 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッドAcrux Dds Pty Ltd 経皮または局所薬物輸送に伴う副作用の処置方法
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
CA2549935A1 (en) 2003-12-17 2005-07-07 Pfizer Products Inc. Treatment of conditions that present with low bone mass by continuous combination therapy with selective prostaglandin ep4 receptor agonists and an estrogen
US20050153946A1 (en) 2003-12-24 2005-07-14 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
CN1921879A (zh) 2003-12-29 2007-02-28 明斯特大学临床医学院 由il-15刺激和活化毛发生长的方法
IL159729D0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
KR100778992B1 (ko) 2004-01-07 2007-11-28 이엘씨 매니지먼트 엘엘씨 체모 성장을 지연시키기 위한 미용 조성물 및 방법
US20060084704A1 (en) 2004-01-28 2006-04-20 Charles Shih Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US20050271597A1 (en) 2004-02-13 2005-12-08 Keith Alec D Prostate hypertrophy treatment composition and method
ES2609688T3 (es) 2004-02-23 2017-04-21 Euro-Celtique S.A. Dispositivo de administración transdérmica de opioides con resistencia al abuso
US8052669B2 (en) 2004-02-25 2011-11-08 Femasys Inc. Methods and devices for delivery of compositions to conduits
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
US7417040B2 (en) 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20050196434A1 (en) 2004-03-04 2005-09-08 Brierre Barbara T. Pharmaceutical composition and method for the transdermal delivery of magnesium
US20050220825A1 (en) 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
CA2558393A1 (en) 2004-03-10 2005-09-22 Schering Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050222106A1 (en) 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
EP1744714A4 (en) 2004-04-07 2009-08-26 Dermatrends Inc Transdermal delivery system for use with basic permeation enhancers
US20050228692A1 (en) 2004-04-08 2005-10-13 Hodgdon Darren W Incentive based health care insurance program
US20050228718A1 (en) 2004-04-13 2005-10-13 Pop Insights Inc. Point of purchase research device
US20050239758A1 (en) 2004-04-21 2005-10-27 Roby Russell R Hormone treatment of multiple sclerosis
US20050239747A1 (en) 2004-04-21 2005-10-27 Pharmaceutical Industry Technology And Development Center Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods
RU2275930C2 (ru) 2004-04-26 2006-05-10 ООО "РусГен" Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции
US20050244522A1 (en) 2004-04-30 2005-11-03 Carrara Dario Norberto R Permeation enhancer comprising genus Curcuma or germacrone for transdermal and topical administration of active agents
US20050250746A1 (en) 2004-05-06 2005-11-10 Matthew Iammatteo Premenstrual dysphoric disorder medication
EP1744750A2 (en) 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
FR2870125B1 (fr) 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
US7899527B2 (en) 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US8048017B2 (en) 2005-05-18 2011-11-01 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US7101342B1 (en) 2004-05-24 2006-09-05 Caillouette James C Detection of menopause status and treatment thereof
WO2005117898A1 (en) 2004-05-26 2005-12-15 Wyeth Compositions and methods for treatment of premenstrual dysphoric disorder
WO2005120517A1 (en) 2004-06-07 2005-12-22 Strides Arcolab Limited Stable liquid suspension formulation comprising synthetic steroids and process for producing the same
US20070196453A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
DE102004028284A1 (de) 2004-06-11 2006-01-05 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System auf Basis eines Schmelzklebstoffs zur Anwendung von Norelgestromin
US7485666B2 (en) 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
US7235563B2 (en) 2004-06-21 2007-06-26 Bristol-Myers Squibb Company Spirocyclic compounds useful as modulators of nuclear hormone receptor function
PE20060378A1 (es) 2004-07-07 2006-06-02 Wyeth Corp Regimenes y kits de progestina ciclica
FR2873585B1 (fr) 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
EP1778187B1 (en) 2004-08-04 2012-05-23 Camurus Ab Compositions forming non-lamellar dispersions
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
US20060034889A1 (en) 2004-08-16 2006-02-16 Macromed, Inc. Biodegradable diblock copolymers having reverse thermal gelation properties and methods of use thereof
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US7879830B2 (en) 2004-09-02 2011-02-01 Wiley Teresa S Hormone replacement composition and method
US20070167418A1 (en) 2004-09-07 2007-07-19 Ferguson Steven W Progesterone/testosterone cream for erectile dysfunction
EP2301557A1 (en) 2004-09-09 2011-03-30 Warburton Technology Limited Trace elements
AR043476A1 (es) 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
WO2006032026A2 (en) 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
US20070254314A1 (en) 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US7338973B2 (en) 2004-09-20 2008-03-04 Janssen Pharmaceutica N.V. Tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
US20060062758A1 (en) 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
EP1796725B1 (en) 2004-09-27 2008-07-23 Pantarhei Bioscience B.V. Treatment or prevention of unscheluded bleeding in women on progestogen containing medication
US20060121102A1 (en) 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US7569725B2 (en) 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
ES2389630T3 (es) 2004-11-10 2012-10-29 Hisamitsu Pharmaceutical Co., Inc. Fármacos para uso externo y parche adhesivo
US20060106004A1 (en) 2004-11-12 2006-05-18 Brody Steven A Unique methods and formulations of bio-identical sex steroids for the treatment of pathophysiologic aberrations of menopause
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US8121886B2 (en) 2004-12-03 2012-02-21 Ryma Technology Solutions Inc. Confidence based selection for survey sampling
US7465587B2 (en) 2004-12-03 2008-12-16 Genzyme Corporation Diagnostic assay device
AT501408B1 (de) 2004-12-07 2011-03-15 Physikalisches Buero Steinmueller Gmbh Biologische oberflächen
EP1824341A4 (en) 2004-12-17 2008-05-21 Bionovo Inc Estrogenic extracts of morus alba and uses thereof
US20060134188A1 (en) * 2004-12-20 2006-06-22 Hans-Peter Podhaisky Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
ITMI20050262A1 (it) 2005-02-21 2006-08-22 Carlo Ghisalberti Sostanze composizioni e metodi di trattamento dell'alopecia
US8703198B2 (en) 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
WO2006105615A1 (en) 2005-04-08 2006-10-12 Ozpharma Pty Ltd Buccal delivery system
JP2008536851A (ja) 2005-04-13 2008-09-11 ユニメド ファーマスーティカルズ インク 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
US7767656B2 (en) 2005-04-25 2010-08-03 Molly S Shoichet Blends of temperature sensitive and anionic polymers for drug delivery
US9205047B2 (en) 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20060252049A1 (en) 2005-05-04 2006-11-09 Shuler Richard O Growth-promoting and immunizing subcutaneous implant
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
AU2006249349B2 (en) 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
NZ563946A (en) 2005-06-03 2012-02-24 Acrux Dds Pty Ltd Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla
ITBO20050388A1 (it) 2005-06-06 2006-12-07 Alfa Wassermann Spa Formulazione mucoadesive utili in dispositivi medici in preparazioni farmaceutiche
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
MX2007015571A (es) 2005-06-09 2008-03-06 Wyeth Corp Composiciones de tanaproget que contienen etinilestradiol.
US20070004693A1 (en) 2005-06-16 2007-01-04 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
CA2612456C (en) 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Gel compositions for topical administration
WO2006138686A1 (en) 2005-06-16 2006-12-28 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
TW200726473A (en) 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
US8461138B2 (en) 2005-06-29 2013-06-11 Warner Chilcott Company, Llc Quadraphasis continuous graduated estrogen contraceptive
US20070010550A1 (en) 2005-07-08 2007-01-11 The Board Of Regents Of The University Of Texas Scopolamine to Reduce or Eliminate Hot Flashes, Night Sweats, and Insomnia
US20070014839A1 (en) 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
DE102005034498A1 (de) 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
US8195403B2 (en) 2005-07-21 2012-06-05 The Invention Science Fund I, Llc Selective resonance of bodily agents
US20070027107A1 (en) 2005-07-29 2007-02-01 Curt Hendrix Compositions and methods for treating estrogen-dependent diseases and conditions
PE20070341A1 (es) 2005-07-29 2007-04-13 Wyeth Corp Derivados de pirrol como moduladores del receptor de progesterona
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
EA200800663A1 (ru) 2005-09-16 2008-10-30 Сириусайенс Аб Способ и средство профилактики и лечения нарушенного дыхания во время сна
US7414142B2 (en) 2005-09-19 2008-08-19 Wyeth 5-aryl-indan-1-one oximes and analogs useful as progesterone receptor modulators
US20070066628A1 (en) 2005-09-19 2007-03-22 Wyeth 5-Aryl-indan-1-ol and analogs useful as progesterone receptor modulators
US7319152B2 (en) 2005-09-19 2008-01-15 Wyeth 5-Aryl-indan-1-one and analogs useful as progesterone receptor modulators
CA2664629A1 (en) 2005-09-27 2007-04-05 Christopher Gregg Oligodendrocyte precursor cell proliferation regulated by prolactin
US20090149434A1 (en) 2005-09-29 2009-06-11 Joseph Podolski Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
WO2007039646A1 (en) 2005-10-06 2007-04-12 Pantec Biosolutions Ag Transdermal delivery system for treating infertility
US7550458B2 (en) 2005-10-18 2009-06-23 Bristol-Myers Squibb Company Tricycloundecane compounds useful as modulators of nuclear hormone receptor function
US8096940B2 (en) 2005-10-19 2012-01-17 Iversync Ii Llc Reproductive management
AU2006304620A1 (en) 2005-10-19 2007-04-26 Scott Josephson Improved reproductive management
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
KR20090008175A (ko) 2005-10-24 2009-01-21 마나와투 바이오텍 인베스트먼츠 엘티디. (엠비아이엘) 배란 주기 모니터링 및 관리
US20070093548A1 (en) 2005-10-25 2007-04-26 Wyeth Use of progesterone receptor modulators
IE20050723A1 (en) 2005-10-28 2007-05-30 Patrick T Prendergast Anti-mineralocorticoid therapy of infection
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN101360488A (zh) 2005-11-22 2009-02-04 史密丝克莱恩比彻姆公司 化合物
CN101360419A (zh) 2005-11-22 2009-02-04 史密丝克莱恩比彻姆公司 化合物
JP2009516695A (ja) 2005-11-22 2009-04-23 スミスクライン ビーチャム コーポレーション 化合物
JP2009516696A (ja) 2005-11-22 2009-04-23 スミスクライン ビーチャム コーポレーション 化学化合物
EP1951216A2 (en) 2005-11-22 2008-08-06 SmithKline Beecham Corporation Chemical compounds
US20070116829A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Pharmaceutical Composition with High-Potency Sweetener
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
GB0524961D0 (en) 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents for systemic effect
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8337814B2 (en) 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
WO2007092085A2 (en) 2005-12-20 2007-08-16 Howard Murad Fragranced therapeutic delivery system
RU2443406C2 (ru) 2005-12-22 2012-02-27 Оцука Фармасьютикал Ко., Лтд. Способ получения содержащих лекарственное вещество восковых матричных частиц, экструдер для применения в способе и лекарственное средство с замедленным высвобождением, содержащее цилостазол
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
SG163525A1 (en) 2005-12-23 2010-08-30 Partnership & Corp Technology Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
AU2006330846A1 (en) 2005-12-27 2007-07-05 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
MY148575A (en) 2005-12-28 2013-04-30 Fresenius Kabi Oncology Ltd A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
JP5285279B2 (ja) * 2005-12-28 2013-09-11 久光製薬株式会社 経皮吸収型製剤
KR100750320B1 (ko) 2006-01-04 2007-08-17 포항공과대학교 산학협력단 쿠커비투릴을 포함하는 젤
US20090186081A1 (en) 2006-01-05 2009-07-23 Lifecycle Pharma A/S Disintegrating Loadable Tablets
KR100784485B1 (ko) 2006-01-18 2007-12-11 한국과학기술연구원 생분해성 온도 감응성 폴리포스파젠계 하이드로젤, 그의제조방법 및 그의 용도
MX2008009177A (es) 2006-01-20 2008-12-05 Pear Tree Pharmaceuticals Inc Metodo para tratar vaginitis atrofica.
WO2007083984A1 (en) 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugate comprising pharmaceutical active compound covalently bound to mucoadhesive polymer and transmucosal delivery method of pharmaceutical active compound using the same
US20100278759A1 (en) 2006-02-08 2010-11-04 Howard Murad Topical Therapeutic Delivery System
CN101389326A (zh) 2006-02-24 2009-03-18 阿克塞拉公司 环木脂体用于治疗Ⅱ型糖尿病和作为避孕药的应用
WO2007106264A2 (en) 2006-03-02 2007-09-20 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
US20070207225A1 (en) 2006-03-03 2007-09-06 Francesco Squadrito Genistein modulated reduction of cardiovascular risk factors
EP2001439A2 (en) * 2006-03-07 2008-12-17 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
KR100746962B1 (ko) 2006-04-04 2007-08-01 한국과학기술연구원 온도 감응성 포스파젠계 고분자-생리 활성 물질 복합체,그의 제조방법 및 그의 용도
RU2008136024A (ru) 2006-04-05 2010-05-10 Вайет (Us) Способы предотвращения и лечения состояний, возникающих в результате местного дефицита эстрогенов
JP2009533341A (ja) 2006-04-07 2009-09-17 ノババックス,インコーポレイテッド 抗細菌、抗真菌、抗酵母、および/または抗ウイルス特性を有するナノ構造組成物
AU2007234724A1 (en) 2006-04-07 2007-10-18 The Johns Hopkins University Compounds, compositions and methods for treating hormone-dependent maladies
WO2007120868A2 (en) 2006-04-14 2007-10-25 Stanley Kepka Bioavailability enhancement of lipophilic drug by use solvent system
US8399012B2 (en) 2006-04-17 2013-03-19 Kimberly-Clark Worldwide, Inc. Degradable therapeutic delivery device
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
US20070254858A1 (en) 2006-04-27 2007-11-01 Cronk Peter J Contraceptive and Acne Medication Combination and Treatment of Acne and Other Diseases with Reduced Side Effects
CN101522174A (zh) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US20070287789A1 (en) 2006-06-07 2007-12-13 Stephen Ray Jones Bleed-resistant colored microparticles
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
US20080021003A1 (en) 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen
US20070292493A1 (en) 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US8288366B2 (en) 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
US7989487B2 (en) 2006-07-06 2011-08-02 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
CA2658496A1 (en) 2006-07-22 2008-01-31 Oxagen Limited 2-{5-fluoro-2-methyl-3-[2-(phenylsulfonyl)benzyl]-1h-indol-yl} acetic acid derivatives and esters thereof having crth2 antagonist activity
DE102006035549A1 (de) 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
US20080026062A1 (en) 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
US20080038219A1 (en) 2006-08-07 2008-02-14 Calgenex Corporation Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof
US20080095831A1 (en) 2006-08-10 2008-04-24 Mc Graw Thomas L Topical formulation of multilamellar vesicles composition for percutaneous absorption of pharmaceutically active agent
US20080038350A1 (en) 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
US20080085877A1 (en) 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
EA200970260A1 (ru) 2006-09-08 2009-08-28 Фоамикс Лтд. Окрашенная или окрашиваемая и вспениваемая композиция и пена
EP2063861B1 (en) 2006-09-15 2015-02-25 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2063870A2 (en) 2006-09-16 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
CA2664427C (en) 2006-10-04 2012-06-05 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
WO2008046085A2 (en) 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US20100168228A1 (en) 2006-10-13 2010-07-01 Reliance Life Sciences Pvt. Ltd. Novel chemotherapeutic agents against inflammation and cancer
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
EP1915986A1 (en) 2006-10-23 2008-04-30 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Lipid growth factor formulations
US8636787B2 (en) 2006-10-25 2014-01-28 Arterial Remodeling Technologies, S.A. Method for expansion and deployment of polymeric structures including stents
DE102006050558B4 (de) 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
US20080103116A1 (en) 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20090214474A1 (en) 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2669094A1 (en) 2006-11-08 2008-05-29 Novavax,Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US7829116B2 (en) 2006-11-14 2010-11-09 Momentive Performance Materials Inc. Adhesive-forming composition and blend of adhesives obtained therefrom
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
AR064014A1 (es) 2006-11-29 2009-03-04 Wyeth Corp Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
EP2097065A2 (en) 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
US20080145423A1 (en) 2006-12-14 2008-06-19 Ajmal Ali Khan Chewable tablet and method of formulating
WO2008079898A1 (en) 2006-12-20 2008-07-03 Pharmwest, Inc. Methods and topical formulations comprising colloidal metal for treating or preventing skin conditions
CN101679362A (zh) 2006-12-20 2010-03-24 拜尔保健公司 用于治疗癌症的 4 -{ 4 - [ ({ 3 -叔丁基 - 1 - [ 3 - (羟基甲基 )苯基 ] - 1 h -吡唑 - 5 -基} -氨基甲酰基)-氨基]-3-氟苯氧基}-n-甲基吡啶-2-甲酰氨及其前药和盐
CA2674078C (en) 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
EA015473B1 (ru) 2007-01-11 2011-08-30 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Инструмент для нанесения объема жидкости на обрабатываемую поверхность, система и способ трансдермального введения физиологически активного вещества в организм больного
MX2009007254A (es) 2007-01-12 2009-08-12 Wyeth Corp Composiciones de tableta en tableta.
AU2008207986A1 (en) 2007-01-22 2008-07-31 Novavax, Inc. Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
IL181217D0 (en) 2007-02-08 2007-07-04 Haim Levy Pharmaceuticalcompositions based on a microemulsion
US8512693B2 (en) 2007-02-14 2013-08-20 Northwestern University Self-assembling membranes and related methods thereof
JP2011512164A (ja) 2007-02-20 2011-04-21 ガルデルマ・リサーチ・アンド・デヴェロップメント 皮膚内への治療物質の送達方法
US20080206156A1 (en) 2007-02-22 2008-08-28 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
WO2008106149A1 (en) 2007-02-28 2008-09-04 Children's Medical Center Corporation Methods for predicting the onset of menarche
US20080214512A1 (en) 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
DE102007011486A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Arzneimittel umfassend wenigstens ein Gestagen
US20080226698A1 (en) 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
MX363435B (es) 2007-03-22 2019-03-22 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
JP5785392B2 (ja) 2007-04-20 2015-09-30 プレグレム エスアーPreglem S.A. 過剰子宮出血の治療におけるプロゲステロンアンタゴニストおよび選択的プロゲステロンモジュレーター
EP1988098A1 (en) 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
WO2008140794A1 (en) 2007-05-11 2008-11-20 The Texas A & M University System Hormone normalization therapy and uses thereof
EP2164498A4 (en) 2007-06-04 2010-09-08 Univ California Pregnancy hormone combination for treatment of autoimmune diseases
US20080312198A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
US20080312197A1 (en) 2007-06-14 2008-12-18 Rodriguez Gustavo C Pharmaceutical products containing hormones and a 25-hydroxy vitamin d compound
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
EP2155205B1 (en) 2007-06-21 2011-12-21 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
ES2310968B1 (es) 2007-06-25 2010-02-08 Italfarmaco, S.A. Uso de estriol en bajas dosis.
CN101827581A (zh) 2007-06-26 2010-09-08 沃纳奇尔科特有限责任公司 用于递送大分子和水溶性药物的阴道内药物递送装置
US8992977B2 (en) 2007-06-27 2015-03-31 Samos Pharmaceuticals, Llc Multi-day delivery of biologically active substances
FR2918277B1 (fr) 2007-07-06 2012-10-05 Coretecholding Nouveau procede de production de formes pharmaceutiques seches hydrodispersibles et les compositions hydrodispersibles ainsi obtenues
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
KR100937625B1 (ko) 2007-08-10 2010-01-20 주식회사 제닉 가용성 웹 공극필름 및 이의 제조방법
US20090060997A1 (en) 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8617100B2 (en) 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
US20100204326A1 (en) 2007-09-06 2010-08-12 Regain Biotechnology Pvt Ltd Novel agents for treatment of ailments and dysfunctions
AR068409A1 (es) 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
EP2191833B1 (en) 2007-09-20 2013-02-13 Shiseido Company, Ltd. Transdermally absorbable preparation
AR066166A1 (es) 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
PL2200588T3 (pl) 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
MX2010003774A (es) 2007-10-08 2010-04-27 Fovea Pharmaceuticals Sa Formulaciones oftalmicas acuosas.
US20090099149A1 (en) 2007-10-11 2009-04-16 Wyeth Bioadhesive film
JP2011500793A (ja) 2007-10-25 2011-01-06 ルピン・リミテッドLupin Limited 制吐薬と経口避妊薬との組み合わせ
BRPI0819245A2 (pt) 2007-11-02 2016-07-19 Acrux Dds Pty Ltd sistema de distribuição transdérmica
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009070794A1 (en) 2007-11-29 2009-06-04 Jackson Gregg A Progesterone-containing compositions and devices
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
FR2924942B1 (fr) 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
US8762865B2 (en) 2007-12-19 2014-06-24 The Iams Company Interactive survey feedback tool
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB0802403D0 (en) 2008-02-08 2008-03-12 Probiox Sa Compositions for the treatment of oxidative stress
TW201008569A (en) 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system
US7960368B2 (en) 2008-03-05 2011-06-14 Everstra, Inc. Bismethylene-17A carbolactones and related uses
US20090232897A1 (en) 2008-03-14 2009-09-17 Bijayananda Sahoo Pharmaceutical compositions comprising conjugated estrogens
EP2285392A4 (en) 2008-04-11 2012-06-06 Bionovo Inc Anticancer methods employing extracts of gleditsia sinensis lam
US20110104289A1 (en) 2008-04-14 2011-05-05 Posi Visionary Solutions Llp Method and pharmaceutical composition for obtaining the plasmatic progesterone levels required for different therapeutic indications
ES2327201B1 (es) 2008-04-23 2010-07-23 Ignacio Umbert Millet Composicion farmaceutica personalizada para el rejuvenecimiento de la piel que contiene acido retinoico.
CA2725578A1 (en) 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
US20090285869A1 (en) 2008-05-14 2009-11-19 Humco Holding Group, Inc. Salt stable lecithin organogel composition
US8426207B2 (en) 2008-05-20 2013-04-23 Cantimer, Inc. Methods, systems and devices for analyzing a biological fluid sample following ion exchange
EP2283363A1 (en) 2008-05-20 2011-02-16 Cantimer Incorporated Methods, systems and devices for analyzing a surfactant-treated biological fluid sample
HUE035770T2 (en) 2008-06-16 2018-05-28 Pfizer Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
WO2009158584A1 (en) 2008-06-27 2009-12-30 Wyeth Dual adhesive technology
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
US20110190201A1 (en) 2008-07-24 2011-08-04 Searete Llc Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100028360A1 (en) 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
IT1392903B1 (it) 2008-07-29 2012-04-02 Marino Salin Composizione comprendente un'associazione di principi attivi per uso nel trattamento topico della calvizie
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
EP2977469A1 (en) 2008-08-28 2016-01-27 Dermtech International Determining age ranges of skin samples
US8540967B2 (en) 2008-09-08 2013-09-24 Hoffman/Barrett, L.L.C. Porphyrazine optical and dual optical/MR contrast and therapeutic agents
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
EP2334285A1 (en) 2008-09-12 2011-06-22 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
JP2012502988A (ja) 2008-09-16 2012-02-02 プレイテックス プロダクツ エルエルシー 月経抑制、避妊、およびホルモン補充療法のための製剤、ならびにその投与方法
US20110250274A1 (en) 2008-09-19 2011-10-13 Shaked Ze Ev Estriol formulations
EP2174650A1 (en) 2008-10-08 2010-04-14 Polichem SA Modified release emulsions for application to skin or vaginal mucosa
EP2218447B1 (en) 2008-11-04 2017-04-19 PharmaSol GmbH Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles
US20110300167A1 (en) 2008-11-04 2011-12-08 Mcmurry Thomas J Cxcr5 receptor compounds
WO2010053548A2 (en) 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Pthr1 receptor compounds
US20110301087A1 (en) 2008-11-04 2011-12-08 Mcbride Edward Crf1 receptor compounds
EP2362779A4 (en) 2008-11-04 2013-03-20 Anchor Therapeutics Inc Cxcr4 receptor compounds
RU2011122482A (ru) 2008-11-04 2012-12-20 Энкер Терапьютикс, Инк. Apj-рецепторы соединения
BRPI0921048A2 (pt) 2008-11-14 2015-12-29 Univ Ewha Ind Collaboration método para preparar microsferas e microsferas produzidas por esse método
US8394759B2 (en) 2008-11-21 2013-03-12 Cymbiotics, Inc. Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
EP2367808A4 (en) 2008-11-25 2012-05-09 Evestra Inc PROGESTATIONAL 3-(6,6-ETHYLENE-17b-HYDROXY-3-OXO-17a-PREGNA-4-ENE-17a-YL) PROPIONIC ACID g-LACTONES
WO2010063080A1 (en) 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
CN102238873A (zh) 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
EP2367429B1 (en) 2008-12-06 2017-06-07 Intra-Cellular Therapies, Inc. Organic compounds
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
NZ593033A (en) 2008-12-06 2013-11-29 Intra Cellular Therapies Inc 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine and 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine derivatives as PDE1 Inhibitors
ES2551325T3 (es) 2008-12-06 2015-11-18 Intra-Cellular Therapies, Inc. Compuestos orgánicos
KR20110096032A (ko) 2008-12-06 2011-08-26 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
WO2010080543A1 (en) 2008-12-18 2010-07-15 Guthery B Eugene Acne vulgaris treatment regimen
EP2384198A4 (en) 2008-12-30 2012-08-08 Endogenx Inc Pharmaceutical compositions and methods of treating neurological insults
JP2012515170A (ja) 2009-01-13 2012-07-05 シェペンズ アイ リサーチ インスティテュート 膣上皮境界潤滑の治療的調節
US20120046518A1 (en) 2009-01-26 2012-02-23 Jennifer Yoakum Estrus Synchronization Preparations & Effective CIDR-Less Protocols
WO2010088203A1 (en) 2009-01-27 2010-08-05 Wisconsin Alumni Research Foundation Therapeutic treatment of cancer and dysplasia of the cervix or vagina using estrogen antagonists
US20110306579A1 (en) 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010093834A2 (en) 2009-02-12 2010-08-19 Incube Labs, Llc Skin penetrating device and method for subcutaneous solid drug delivery
US8202736B2 (en) 2009-02-26 2012-06-19 The Governing Council Of The University Of Toronto Method of hormone extraction using digital microfluidics
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
WO2010104937A2 (en) 2009-03-10 2010-09-16 Northwestern University Lateral flow strip and uses thereof
US20120142645A1 (en) 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
WO2010105995A2 (en) 2009-03-17 2010-09-23 Intervet International B.V. Zoo-technical drug delivery device
CN102413813B (zh) 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc Transdermal delivery
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
CA2758746A1 (en) 2009-04-14 2010-10-21 Medortus (Uk) Ltd. Gel compositions for administration of pharmaceutically active compounds
US8694358B2 (en) 2009-04-14 2014-04-08 Vital Insights Inc. Systems, methods, and media for survey management
EP2419398A4 (en) 2009-04-14 2012-11-28 Infiniton Ab A prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
EP2421367A4 (en) 2009-04-23 2012-05-23 Univ Cincinnati Allantoin administration for the treatment of neurodegenerative disease and neurotrauma
US8344007B2 (en) 2009-04-23 2013-01-01 The Hong Kong Polytechnic University Water-soluble polymer-based cantharimides as potentially selective anti-tumor agents
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
US8568374B2 (en) 2009-05-04 2013-10-29 Merck Sharp & Dohme B.V. Intrauterine system
WO2010129858A1 (en) 2009-05-08 2010-11-11 Georgia State University Research Foundation Compounds and compositions comprising cdk inhibitors and methods for the treatment of cancer
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
EP2437730A4 (en) 2009-05-20 2014-02-26 Lingual Consegna Pty Ltd Buccal and/or sublingual therapeutic formulation
US8658628B2 (en) 2009-06-18 2014-02-25 Karan Y. Baucom Hormone delivery system and method
JP5664871B2 (ja) 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
WO2010149273A1 (de) 2009-06-23 2010-12-29 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische zusammensetzung zur notfallempfängnisverhütung
FR2947178B1 (fr) 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
CN101940790B (zh) 2009-07-01 2012-07-25 杨明京 一种新型促渗剂组合物及其在透皮给药系统中的应用
TR201907783T4 (tr) 2009-07-06 2019-06-21 Aerpio Therapeutics Inc Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US8618083B2 (en) 2009-07-31 2013-12-31 Duquesne University Of The Holy Spirit Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
KR101118587B1 (ko) 2009-08-17 2012-06-12 포항공과대학교 산학협력단 감응성 고분자 캡슐 및 그 제조방법
US8577716B2 (en) 2009-09-17 2013-11-05 Therapeuticsmd, Inc. System and method of ongoing evaluation reporting and analysis
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US8882748B2 (en) 2009-10-08 2014-11-11 Palo Alto Research Center Incorporated Transmucosal drug delivery device and method including chemical permeation enhancers
US20120269721A1 (en) 2009-10-12 2012-10-25 The Regents Of The University Of California Targeted nanoclusters and methods of their use
US20110086825A1 (en) 2009-10-13 2011-04-14 Chatroux Sylvia S Therapeutic vaginal emollient
CA2814237A1 (en) 2009-10-15 2011-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Water soluble drug-solubilizer powders and their uses
US20120316496A1 (en) 2009-10-16 2012-12-13 Michael Hoffmann Use of compositions to coat catheter balloons and coated catheter balloons
BR112012009306A2 (pt) 2009-10-19 2016-06-07 Population Coucil Inc método para regeneração de mielina em um paciente
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP2506867B1 (en) 2009-12-02 2014-10-08 Cardio3 Biosciences S.A. Pharmaceutical compositions for the stimulation of stem cells.
WO2011073995A2 (en) 2009-12-14 2011-06-23 Lincoln Pharmaceuticals Limited Liquid vaginal spray of progesterone
CN102753180A (zh) 2009-12-17 2012-10-24 人口委员会股份有限公司 Nestorone*/雌二醇透皮凝胶
CA2784847C (en) 2009-12-18 2017-11-21 Molly Sandra Shoichet Injectable polymer composition for use as a cell delivery vehicle
WO2011079047A1 (en) 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
TWI482645B (zh) 2010-01-07 2015-05-01 Teikoku Seiyaku Kk 含有待克菲那(diclofenac)羥乙基吡咯啶之外用油性敷貼劑
US8709451B2 (en) 2010-01-20 2014-04-29 University Of Utah Research Foundation Stable nanoemulsions for ultrasound-mediated drug delivery and imaging
WO2011089620A2 (en) 2010-01-25 2011-07-28 Concept Medical Research Private Limited A method and an insert able medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent
JP5913136B2 (ja) 2010-02-08 2016-04-27 プレーリー ファーマシューティカルズ、エルエルシー 糖質コルチコイド感作物質としてのプロゲストーゲンの使用方法
WO2011098262A2 (en) 2010-02-09 2011-08-18 Universität Bremen P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth
US20130072466A1 (en) 2010-02-22 2013-03-21 Industry-Academic Cooperation Foundation, Yeungnam University Composition containing placenta extracts
WO2011109809A2 (en) 2010-03-05 2011-09-09 New Agriculture, Inc A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
CA2789238A1 (en) 2010-03-09 2011-09-15 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
WO2011112822A2 (en) 2010-03-10 2011-09-15 University Of Florida Research Foundation. Inc. Implantable therapeutic device and methods of making
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
WO2011120044A1 (en) 2010-03-26 2011-09-29 Duke University Conjugated neuroactive steroid compositions and methods of use
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
DE102010003494A1 (de) 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
US20110250259A1 (en) 2010-04-12 2011-10-13 Kevin Buckman Method of treating and preventing breast diseases and breast cancer with medicated formula
US20130131028A1 (en) 2010-04-13 2013-05-23 Johns Hopkins University Methods for treatment of sleep-related breathing disorders
WO2011128336A1 (en) 2010-04-15 2011-10-20 Bayer Pharma Aktiengesellschaft Very low-dosed solid oral dosage forms for hrt
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
RU2603479C2 (ru) 2010-05-28 2016-11-27 М.Алфабет 1, ЛЛС. Комбинированная терапия для кожных нарушений
CN102258455B (zh) 2010-05-28 2014-09-17 上海市计划生育科学研究所 一种甾体激素类涂膜剂及其制备方法
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc Organic compounds
BRPI1002601A2 (pt) 2010-06-01 2012-03-13 Univ Fed De Ouro Preto produto e processo de preparo e de nanocápsulas poliméricas caracterizadas contendo cloxacilina aplicáveis ao tratamento da mastite bovina
JP2012020991A (ja) 2010-06-16 2012-02-02 Takasago Internatl Corp 経皮吸収促進剤、及びこれを含有する皮膚外用製剤
CN103096870B (zh) 2010-06-17 2017-04-19 动量制药公司 调节毛发生长的方法和组合物
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
EP2399566A1 (en) 2010-06-28 2011-12-28 Laboratoire HRA Pharma Once-a-month method of contraception
KR101209266B1 (ko) 2010-06-30 2012-12-06 한국과학기술연구원 생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
EP2407157A1 (en) 2010-07-13 2012-01-18 Koninklijke Philips Electronics N.V. Lipid bilayer carrier for drugs or imaging agents
KR20120011344A (ko) 2010-07-21 2012-02-08 에스케이케미칼주식회사 고분자 미립구의 제조방법 및 그 방법에 의해 제조된 고분자 미립구
BRPI1002486B1 (pt) 2010-07-22 2017-07-18 Evidence Soluções Farmacêuticas Ltda Epp Stabilized topical composition and process of obtaining composition stable topic
US20120128733A1 (en) 2010-07-28 2012-05-24 Philippe Perrin Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US20120046264A1 (en) 2010-08-17 2012-02-23 Biosante Pharmaceuticals, Inc. Commercial scale production methods for transdermal hormone formulations
US8435972B2 (en) 2010-09-02 2013-05-07 Emory University Method for the treatment of central nervous system cancers and compositions related thereto
US20120064135A1 (en) 2010-09-15 2012-03-15 Norac Pharma Benzoyl Peroxide Composition, Methods for Making Same, and Pharmaceutical or Cosmetic Formulations Comprising Same, and Uses Thereof
BRPI1003661A2 (pt) 2010-09-15 2013-01-08 Libbs Farmaceutica Ltda associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
ES2386177B1 (es) 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
DE102010047714A1 (de) 2010-10-06 2012-04-12 Justus-Liebig-Universität Derivate von Steroidbenzylaminen mit antiparasitärer, antibakterieller, antimykotischer und/oder antiviraler Wirkung
US20120101073A1 (en) 2010-10-22 2012-04-26 Galleon Pharmaceutical, Inc. Novel Method For Treating Breathing Disorders or Diseases
WO2012055814A1 (en) 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compound inducing lbpa accumulation for inhibiting cell-to-cell transmission of hiv
WO2012055840A1 (en) 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
MX2014005367A (es) 2011-11-04 2014-07-09 Bayer Pharma AG 18-metil-6,7-metilen-3-oxo-17-pregn-4-en-21,17b-carbolactona, preparados farmaceuticos que contienen los compuestos mencionados y su uso en la terapia de la endometriosis.
US9149537B2 (en) 2010-11-04 2015-10-06 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of traumatic brain injury
DK2640389T3 (en) 2010-11-17 2015-03-09 Hexal Ag Transdermal therapeutic system comprising buprenorphine
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
ES2618907T3 (es) 2010-12-03 2017-06-22 Allergan, Inc. Composiciones farmacéuticas en crema que comprenden oximetazolina
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
KR101424163B1 (ko) 2010-12-24 2014-08-01 주식회사 삼양바이오팜 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법
DE102011002934A1 (de) 2011-01-20 2012-07-26 Bayer Schering Pharma Ag CB2 Agonisten zur Behandlung und Vorbeugung der Endometriose
JP2014503586A (ja) 2011-01-24 2014-02-13 アンテリオス, インコーポレイテッド 油組成物
KR20140004186A (ko) 2011-01-24 2014-01-10 안테리오스, 인코퍼레이티드 표면활성제 조성물
KR101376237B1 (ko) 2011-01-25 2014-03-21 전북대학교산학협력단 사이클릭 에이디피 라이보스와 그 유도체 및 cd38을 이용한 수정능 조절 방법
CA2825134A1 (en) 2011-01-25 2012-08-02 Kissei Pharmaceutical Co., Ltd. Indole derivative, and pharmacologically acceptable salt thereof
TW201309670A (zh) 2011-01-25 2013-03-01 Kissei Pharmaceutical 吲哚衍生物或其藥理學上容許之鹽
US20140031323A1 (en) 2011-02-15 2014-01-30 Ramiro M. Perez Transdermal hormone composition and combined static-cyclic delivery
US20140024590A1 (en) 2011-02-18 2014-01-23 Yale University KRAS-Variant And Endometriosis
WO2012116277A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
CA2828877A1 (en) 2011-03-03 2012-09-07 Vanderbilt University 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
WO2012121874A1 (en) 2011-03-04 2012-09-13 Wake Forest University Health Sciences Encapsulated cells for hormone replacement therapy
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
WO2012127501A2 (en) 2011-03-11 2012-09-27 Sanzyme Limited Composition for improving endometrial thickness during ovarian stimulation
US9474911B2 (en) 2011-03-29 2016-10-25 Photokinetix Holdings Inc. Delivery of large molecular weight biologically active substances
EP3238709A1 (en) 2011-04-28 2017-11-01 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
AR082266A1 (es) 2011-05-13 2012-11-28 Univ Nac Del Litoral Microparticula inyectable de liberacion controlada
EA201391701A1 (ru) 2011-05-15 2014-04-30 Тримел Биофарма Срл Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения
WO2012158483A2 (en) 2011-05-16 2012-11-22 Avery Dennison Corporation Adhesive containing microparticles
KR101481859B1 (ko) 2011-05-20 2015-01-14 에스케이케미칼주식회사 초기 약물 방출이 감소된 고분자 미립자의 제조방법 및 그 방법에 의해 제조된 고분자 미립자
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
WO2012166909A1 (en) 2011-06-03 2012-12-06 Galleon Pharmaceuticals, Inc. Compositions and methods for treating breathing control disorders or diseases
CN105853445A (zh) 2011-06-06 2016-08-17 橡冠科学研究院 采用芯吸释放窗口的药物递送装置
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
WO2012171793A1 (en) 2011-06-13 2012-12-20 Parthenogen Sagl Selective cns delivery of mifepristone (ru486) to modulate the timing of the spontaneous lh surge during follicular stimulation cycles
US20130004619A1 (en) 2011-06-28 2013-01-03 Kemin Industries, Inc. Method of Forming Encapsulated Compositions with Enhanced Solubility and Stability
WO2013011501A1 (en) 2011-07-20 2013-01-24 Perrigo Israel Pharmaceuticals Ltd Topical oily foam compositions
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
KR101302557B1 (ko) 2011-08-16 2013-09-02 충북대학교 산학협력단 생리활성물질 함유 미세입자를 포함하는 약물전달계가 고정화된 고분자 생체 재료의 제조방법
CN103732216A (zh) 2011-08-16 2014-04-16 默沙东公司 无机基质和有机聚合物组合用于制备稳定的无定形分散体的用途
WO2013081685A1 (en) 2011-08-19 2013-06-06 The Trustees Of Princeton University C-halogen bond formation
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
EP2741757B1 (en) 2011-09-11 2018-05-16 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
US20150064155A1 (en) 2011-09-23 2015-03-05 Trustees Of Tufts College Methods for treatment of cervical insufficiency
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
BR112014008328A2 (pt) 2011-10-07 2017-04-18 Florida State Univ Res Found mecanismo de entrega nasal para uso profilático e pós-agudo de progesterona e/ou seu enantiômero para uso no tratamento de traumatismos crânio-encefálico leves
US8721331B2 (en) 2011-10-11 2014-05-13 Puthalath Koroth Raghuprasad Oral transmucosal drug delivery device
US9828458B2 (en) 2011-10-17 2017-11-28 Temple University—Of the Commonwealth System of Higher Education Silica particles coated with β-cyclodextrin for the removal of emerging contaminants from wastewater
US9120766B2 (en) 2011-10-21 2015-09-01 Amri Ssci, Llc Methods of making cocrystals
US20140271884A1 (en) 2011-10-25 2014-09-18 The Trustees Of Princeton University High-loading nanoparticle-based formulation for water-insoluble steroids
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
KR20140088199A (ko) 2011-11-04 2014-07-09 애자일 쎄라퓨틱스, 인크. 경피 전달 조성물 및 방법
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
US20130122051A1 (en) 2011-11-15 2013-05-16 Pharmaceutics International, Inc. Methods of preparing progesterone pharmaceutical compositions
US20120128683A1 (en) 2011-11-22 2012-05-24 Shantha Totada R Autism treatment
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2014015900A (es) 2012-06-18 2015-07-17 Therapeuticsmd Inc Formulaciones de progesterona.
MX2014006256A (es) 2011-11-23 2014-10-24 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
BR112014031914A2 (pt) 2012-06-18 2017-06-27 Therapeuticsmd Inc cápsula de estradiol solúvel para inserção vaginal
US20150031654A1 (en) 2012-06-18 2015-01-29 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9334538B2 (en) 2011-12-06 2016-05-10 Annabelle Rodriguez Oquendo Method for pre-screening and correlation of underlying SCARB1 gene variation to infertility in women and therapeutic use of progestational and other medications in treatment
WO2013088254A1 (en) 2011-12-12 2013-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system comprising buprenorphine
KR101278204B1 (ko) 2011-12-22 2013-06-27 경북대학교 산학협력단 다중 약물전달계를 갖는 생체의료용 금속합금 재료의 제조방법
US9282995B2 (en) 2011-12-22 2016-03-15 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
EP2802596A1 (en) 2012-01-09 2014-11-19 Anchor Therapeutics, Inc. Apj receptor compounds
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20150202211A1 (en) 2012-06-18 2015-07-23 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20150045335A1 (en) 2013-01-25 2015-02-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositons and methods
WO2013113690A1 (en) 2012-01-31 2013-08-08 Grünenthal GmbH Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
WO2013130535A1 (en) 2012-02-27 2013-09-06 Newgen Biopharma Corporation Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
US20130225412A1 (en) 2012-02-28 2013-08-29 Soroush Sardari Lodriche Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment
MX356427B (es) 2012-02-29 2018-05-29 Braun Melsungen Ag Emulsion que contiene hormona.
FR2988609B1 (fr) 2012-03-30 2015-09-04 Commissariat Energie Atomique Formulation pour l'hormonotherapie
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
FR2988610B1 (fr) 2012-03-30 2014-10-31 Effik Progestatif co-micronise avec un polymere portant le groupe pyrrolidone, composition et utilisations
WO2013158454A2 (en) 2012-04-18 2013-10-24 Siemens Healthcare Diagnostics Inc. Compounds and methods for preparation of conjugate reagents
CA2887352A1 (en) 2012-05-09 2013-11-14 Sio2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
US20130317315A1 (en) 2012-05-22 2013-11-28 Tony V. Lu Method of age management
ITMI20120913A1 (it) 2012-05-28 2013-11-29 Nicoletta Maxia Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
UA114106C2 (xx) 2012-05-31 2017-04-25 Спосіб лікування прогестерон-залежного стану антипрогестином
US20140370084A1 (en) 2013-06-18 2014-12-18 Therapeuticsmd, Inc. Estradiol formulations and therapies
WO2014004424A1 (en) 2012-06-26 2014-01-03 Temple University - Of The Commonwealth System Of Higher Education Method for detecting injury to the brian
WO2014001905A1 (en) 2012-06-27 2014-01-03 Medincell Biodegradable drug delivery for hydrophobic compositions
WO2014009434A1 (en) 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
WO2014012117A1 (en) 2012-07-13 2014-01-16 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
US20150272934A1 (en) 2012-07-25 2015-10-01 Sova Pharmaceuticals, Inc. Use of cse inhibitors for the treatment of cutaneous injuries or conditions and sleep-related breathing disorders
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
US20140235631A1 (en) 2012-07-27 2014-08-21 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
EP2877184B1 (en) 2012-07-27 2019-09-04 Glia Llc Compositions and treatment for eye diseases and disorders
KR101480363B1 (ko) 2012-07-30 2015-01-09 한국과학기술연구원 분해 속도 조절이 가능한 이온기를 가지는 포스파젠계 고분자, 그의 제조방법 및 그의 용도
CN107582544A (zh) 2012-08-24 2018-01-16 英特格拉斯疗法有限公司 用于增强治疗剂透皮递送的化学组合物和方法
EP2708213A1 (en) 2012-09-13 2014-03-19 PAT&Co bvba Multipurpose ethylene vinyl acetate fibrous drug delivery systems for long-term implantation or insertion
WO2014052792A1 (en) 2012-09-28 2014-04-03 Sio2 Medical Products, Inc. Halogenated or parylene polymer coating
EP2716291B1 (en) 2012-10-08 2019-11-27 Universität Ulm Combination of opioids and anticancer drugs for cancer treatment
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
WO2014066442A2 (en) 2012-10-24 2014-05-01 Emory University Methods of managing childhood cerebral injury
US20140127185A1 (en) 2012-11-02 2014-05-08 Emory University Methods and compositions using neuroprotective steroids and thrombolytic agents
US20150290171A1 (en) 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
US20150297733A1 (en) 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
EP2732824A1 (en) 2012-11-16 2014-05-21 Ceva Sante Animale Compositions and methods for increasing reproduction performance in non human mammals using alpha-beta-linked follicle stimulating hormone
WO2014081598A1 (en) 2012-11-20 2014-05-30 The Brigham And Women's Hospital, Inc. Diagnosis and treatment of endometriosis and related conditions
NZ707825A (en) 2012-12-06 2019-06-28 Bayer Pharma AG Novel benzimidazole derivatives as ep4 antagonists
CA2894653A1 (en) 2012-12-11 2014-06-19 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9498539B2 (en) 2012-12-27 2016-11-22 Molly Sandra Shoichet Affinity-based controlled release system
US20140186332A1 (en) 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
KR101586789B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 양이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma

Also Published As

Publication number Publication date
JP2015520236A (ja) 2015-07-16
ZA201500212B (en) 2017-04-26
US10052386B2 (en) 2018-08-21
EP2861233A1 (en) 2015-04-22
AU2013277235B2 (en) 2018-04-19
AU2013277233A1 (en) 2015-01-22
JP6298460B2 (ja) 2018-03-20
CA2876947A1 (en) 2013-12-27
BR112014031837A2 (pt) 2017-06-27
JP6342389B2 (ja) 2018-06-13
AU2013277233B2 (en) 2018-05-31
CA2876964A1 (en) 2013-12-27
AU2018222947A1 (en) 2018-09-20
US20130338122A1 (en) 2013-12-19
BR112014031824A2 (pt) 2017-06-27
JP2015520235A (ja) 2015-07-16
EP2861233B1 (en) 2019-11-06
WO2013192250A1 (en) 2013-12-27
EP3560500A1 (en) 2019-10-30
EP2861234A4 (en) 2015-10-28
EP2861234B1 (en) 2019-03-27
EP2861234A1 (en) 2015-04-22
WO2013192248A1 (en) 2013-12-27
US20150148323A1 (en) 2015-05-28
AU2013277235A1 (en) 2015-01-22
MX2014015897A (es) 2015-03-03
US20190008968A1 (en) 2019-01-10
EP2861233A4 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
NZ620473A (en) Compositions and methods for lowering triglycerides without raising ldl-c levels
PH12014501561B1 (en) Therapeutically active compounds and their methods of use
DK2132317T3 (da) Delta-8-desaturaser og anvendelse heraf i fremstillingen af polyumættede fedtsyrer
WO2011060945A3 (en) Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases
IL217572A (en) 1,3-propanedisulfonic acid esters, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
IL216876A (en) Cationic lipid, lipid formulations comprising same and use thereof in the preparation of therapeutic agents for delivering to cells
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
BR112013013402A2 (pt) combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos
BR112012008164A2 (pt) método para a preparação de ácido 2,5-furanodicarbloxílico e seus ésteres
EP2521447A4 (en) Fatty acid fumarate derivatives and their uses
PH12016500216A1 (en) Stable pharmaceutical composition and methods of using same
MX2013005654A (es) Composiciones y metodos para la produccion de acido 3-hidroxipropionico.
PL2408426T3 (pl) Kompozycje dooczne na bazie wielonienasyconych kwasów tłuszczowych omega-3 i omega-6
EA201270780A1 (ru) С-3 модифицированные производные бетулиновой кислоты в качестве ингибиторов созревания вич
PT2544536T (pt) Conjugados de ácido gordo e quetiapina, processo de preparação e utilização do destes
EP2846779A4 (en) Compositions of statins and omega-3 fatty acids
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
SG10201801321XA (en) Formulations of quinones for the treatment of ophthalmic diseases
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
EP2498602A4 (en) Stabilized formulations of fatty acids
WO2012128587A3 (en) Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor
EA201590026A1 (ru) Выработка длинноцепочечных полиненасыщенных жирных кислот в растительных клетках
IL220679A (en) Production method of solid preparations containing alkaline active pharmaceutical ingredients and the solid preparations produced by the method
EP2532668A4 (en) Optically active 2-hydroxy tetrahydrothienopyridine derivatives, preparation method and use in manufacture of medicament thereof